Protecting a blockbuster diabetes treatment for AstraZeneca
AstraZeneca AB
Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini
Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Finnegan secures favorable ITC ruling related to innovative electric SUVs for BMW
BMW of North America, LLC and Bayerische Motoren Werke AG
Finnegan fights for Sony’s “exceedingly famous” mark
Sony Group Corporation
Experience
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al. Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Experience
Prosecuting patents for startup Hutchison Medipharma Prosecuting patents for startup Hutchison Medipharma
Hutchison Medipharma
Experience
Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal
Principia Biopharma
Experience
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc. Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.
1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley
Experience
Ferring B.V. v. Allergan, Inc. Ferring B.V. v. Allergan, Inc.
1:12-cv-02650, S.D.N.Y., Judges Cott, Sweet
Experience
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp. Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.
1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams
Experience
Ferring B.V. v. Watson Laboratories, Inc. Ferring B.V. v. Watson Laboratories, Inc.
3:11-cv-00481, D. Nev., Judges Cooke, Jones, McKibben
2:15-cv-04222, D.N.J., Judges Chesler, Hayden, Waldor
Experience
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc. Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
3:08-cv-01583, D.N.J., Judges Cooper, Goodman, Hughes
Experience
District court ruling maintains patent and regulatory protection of Otsuka’s Abilify® District court ruling maintains patent and regulatory protection of Otsuka’s Abilify®
3:07-cv-01000, D.N.J., Judges Cooper, Goodman, Hughes
11-1126, -1127, Fed. Cir., Judges Lourie, Moore, Reyna
Experience
A high-impact result for R&D licensing programs in the pharmaceutical industry A high-impact result for R&D licensing programs in the pharmaceutical industry
0:98-cv-07164; 0:00-cv-07057; 0:05-cv-60158, S.D. Fla., Judge Jordan
03-1354, -1355, -1386, -1387, Fed. Cir., Judges Michel, Lourie, Dyk
Experience
Aventis Pharma, S.A. v. Baxter Healthcare Corp. Aventis Pharma, S.A. v. Baxter Healthcare Corp.
1:06-cv-00636, D. Del., Judge Sleet
Experience
Finnegan client Elan protected against antitrust claims based on ANDA settlement Finnegan client Elan protected against antitrust claims based on ANDA settlement
03-13605, 11th Cir., Judges Birch, Dowd, Wilson
1:00-cv-03481, S.D. Fla., Judge Jordan
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.